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Jennifer Kealy; Susanne S. Pedersen, PhD
Background—Technological advancements of left ventricular assist devices (LVAD) have created today’s potential for
extending the lives of patients with end-stage heart failure. Few studies have examined the effect of LVAD therapy on
patient-reported outcomes (PROs), such as health status, quality of life, and anxiety/depression, despite poor PROs predicting
mortality and rehospitalization in patients with heart failure. In this systematic review, we provide an overview of available
evidence on the impact of LVAD therapy on PROs and discuss recommendations for clinical research and practice.
Methods and Results—A systematic literature search identified 16 quantitative studies with a sample size10 (meanSD
age50.112.6 years) that examined the impact of LVAD therapy on PROs using a quantitative approach. Initial
evidence suggests an improvement in health status, anxiety, and depression in the first few months after LVAD
implantation. However, PRO scores of patients receiving LVAD therapy are still lower for physical, social, and
emotional functioning compared with transplant recipients. These studies had several methodological shortcomings,
including the use of relatively small sample sizes, and only a paucity of studies focused on anxiety and depression.
Conclusions—There is a paucity of studies on the patient perspective of LVAD therapy. To advance the field of LVAD
research and to optimize the care of an increasingly growing population of patients receiving LVAD therapy, more
well-designed large-scale studies are needed to further elucidate the impact of LVAD therapy on PROs. (Circ Heart
Fail. 2011;4:714-723.)
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Worldwide heart transplantation offers hope to 3500patients with advanced heart failure each year, but there
are still 15 000 patients on transplant waiting lists in urgent
need of a donor heart.1 Driven by this significant shortage of
donor hearts and a simultaneous increase in the incidence of
heart failure, the first concepts of mechanical circulatory support
from the early 1970s have been transformed into highly ad-
vanced devices capable of long-term support for patients with
end-stage heart failure. The most commonly used long-term
devices are left ventricular assist devices (LVADs).2,3 Left
ventricular assist devices can be divided into 2 main types: (1)
the pulsatile pumps that mimic the natural pulsing action of the
heart and (2) the continuous flow pumps that can be subdivided
into either centrifugal or axial flow pumps.4
Editorial see p 680
Clinical Perspective on p 723
The primary focus of most LVAD studies has been on the
clinical aspects of this therapy, including the efficacy of
different device types, device settings, and alternative thera-
pies (eg, optimal medical treatment and heart transplantation)
in enhancing survival and reducing complications. Only a
subset of LVAD studies have examined the impact of LVAD
therapy on patient-reported outcomes (PROs), such as health
status, anxiety, and depression.5 This is unfortunate because
PROs can be used to assess the effectiveness of treatment, to
enhance the quality of care and management of patients, and to
help allocate resources to patients who need them the most.6,7 In
addition, poor health status has predicted mortality and rehospi-
talization in patients with coronary artery disease and heart
failure, independent of traditional biomedical risk factors.9 This
information cannot be extrapolated from information standardly
available in patients’ medical records or from a proxy.7
In addition to health status, LVADs may also have an
effect on psychological morbidity and feelings of worry and
stress.10–14 Device type and settings might influence the level
of psychological morbidity because patients receiving pulsa-
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tile LVAD therapy have a higher rate of complications and
are bothered by the clicking noise from the device.15 In other
heart failure populations, psychological morbidity has been
associated with poor treatment adherence, poor self-efficacy,
and an unhealthy lifestyle.15,16 Yet, it is not known whether
patients receiving LVAD therapy who have psychological
problems are identified and, hence, treated.
In the future, LVAD therapy is likely to be indicated as a
bridge to transplantation and as destination therapy world-
wide, thereby providing much optimism for the treatment of
more heart failure patients in the future.17 To optimize the
management of this growing group of patients, we need to
know the impact of LVAD therapy on patients from a patient
perspective.12 Only with such knowledge are we able to
improve care after LVAD implantation and to provide pa-
tients and families with all the necessary information that
they need for effective decision making regarding whether
LVAD implantation is aligned with their own preferences and
goals.
Hence, the objectives of this systematic review are to
provide a detailed overview of available evidence on the
impact of LVAD therapy on PROs and suggest recommen-
dations for clinical research and practice.
Methods
Literature Search
The first author (C.B.) performed a literature search on PubMed from
January 1980 to May 2011 using a combination of the following
search terms: LVAD, left ventricular assist device, anxiety, depres-
sion, health status, quality of life, emotional distress, psychological
distress, psychological morbidity, and psychosocial. Only full-text
empirical studies with a sample size 10, examining the impact of
LVAD therapy on PROs assessed by standardized clinical interviews
or standardized and validated questionnaires, were eligible for
inclusion. Articles found by reference searching and articles for
which inclusion was questionable were checked by the last author
(S.S.P.), after which a consensus was reached between both authors
(C.B. and S.S.P.). Of the 250 candidate articles, 26 were identified
that matched the inclusion criteria. Sixteen studies10–14,18–28 ema-
nated largely from the same 4 cohorts, as reported in 1 of the other
articles. From each cohort, only the most recent article was included
(ie, articles with the most optimal study design and largest sample
size), except for 2 extra articles that compared 2 groups of patients
receiving LVAD therapy with 2 different devices.12,18,19,25–27 Hence,
the current review is based on 16 studies (Figure).
Literature Overview
Detailed information on the 16 studies included in this review are
presented in Table 1 and Table 2. The descriptive data detailed later
are stratified by studies on pulsatile (Table 1) vs continuous-flow
(Table 2) devices. Studies in which patients receiving therapy via
both pulsatile and continuous-flow devices were included and were
placed in the continuous-flow device table (Table 2).
For the pulsatile devices, the median number of patients included
in the 7 studies was 30 (meanSD, 36.027.2), with the number of
patients receiving therapy via LVADs ranging from 10 to 78. The
proportion of men ranged from 60% to 99%, and the mean age of
study participants was 47.013.5 (range, 29–67) years. Three
studies29–31 (42.9%) used a cross-sectional study design, 4 stud-
ies12,26,32,33 (57.1%) used a prospective (comparative) study design,
of which 2 (28.6%) were a randomized controlled trial.26,33 In most
studies, the baseline assessment was conducted before hospital
discharge, which varied between 1 and 2 weeks12 to 1 month after
LVAD implantation.32 The 3 cross-sectional studies used a variety of
assessment times ranging from 6 weeks after implantation29,30 to
up to 2 months after LVAD implantation.31 Two studies26,32 com-
pared the PROs of LVAD patients with transplant recipients or
patients receiving optimal medical treatment. Of all studies, 4
(57.1%) focused on health status,12,26,32,33 2 (28.6%) on anxiety,30,32
and 5 (71.4%) on depression26,29–32; 2 studies (28.6%) focused on
both anxiety and depression.30,32
For the continuous-flow devices, the median number of patients
included in the 9 studies was 41 (meanSD, 201229.5), with the
number of LVAD patients ranging from 17 to 655. The proportion of
men ranged from 76% to 100% across studies, and the meanSD
age of study participants was 51.515.7 (range, 46–62.5) years.
Two studies (22%) used a cross-sectional study design,19,34 1 (11%)
used a retrospective design,35 and 6 (66.7%) used a prospective
(comparative) study design.18,25,27,36–38 The baseline assessment was
performed within 1 month after LVAD implantation in the prospec-
tive studies. The retrospective study35 assessed PROs at 12 months
after LVAD implantation, and the cross-sectional studies19,35 in-
cluded patients ranging from 2 to 135 months after LVAD implan-
tation. Two studies19,36 compared the PROs of LVAD patients with
their partners or with transplant recipients. Of all studies, 8 (88.8%)
focused on health status,18,25,27,34–38 whereas 1 study (11%) focused
on depression.19
Results
PROs in Studies on Pulsatile Devices
The studies on the first generation of pulsatile LVADs
(Thoratec TCI, Heartmate VE/IP [Thoratec Inc, Pleasanton,
CA]; Novacor LVAS [WorldHeart Inc, Oakland, CA]; EXCOR
[Berlin Heart AG, Berlin, Germany]; or Toyobo LVAD
[Toyobo Ventricular Assist Systems, Toyobo, Osaka Japan])
assessed health status using a prospective design with a
Figure. Flow chart of article selection.
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variety of instruments (Table 1). All studies found a signifi-
cant improvement in the mean health status score (ie, the
Minnesota Living with Heart Failure Questionnaire [MLHFQ]) or
in at least 2 subdomain scores (ie, the Short-Form Health
Survey 36 [SF-36], the Sickness Impact Profile, the LVAD
Stressor Scale, and the Quality of Life Index [QoL Index]) at
follow-up compared with baseline. The improvement in
health status seemed to reach a plateau at 3 months after
LVAD implantation. The results showed that, during this
period, physical disability becomes less prominent and pa-
tients feel less fatigued and sleep better, thereby increasing
the ability of self-care and ambulation.12 The impact of the
degree of physical disability on health status was also
indicated in a recent trial that randomized LVAD patients to
an exercise training program versus usual-care. The outcomes
demonstrated that improvement in physical exercise capacity
in patients in the treatment arm led to a better health status
compared with that of the patients in the control arm.33
Despite improvements in physical functioning, many patients
may experience psychosocial problems and impaired psycho-
logical well-being, especially at 1 month after implanta-
tion.12,21 The psychological symptoms seem to originate from
feelings of sadness, helplessness, irritability, feeling useless
to others, and having a sense of loss of control over one’s
life12,21; and seem to be associated with worrying about
LVAD malfunction, complications, waiting for a donor heart,
and being away from family.12 Depression and anxiety are
correlated with LVAD noise, driveline problems, and infec-
tion (P0.05 for all).30 The prevalence rates of anxiety and
depression varied widely across the 6 studies that included a
semistructured diagnostic interview using Diagnostic and
Statistical Manual of Mental Disorders (4th Edition) criteria,
the Symptom Checklist-90, the Beck Depression Inventory,
or the Mini-Mental State Examination (Table 2). Some
studies found that only 2% of LVAD patients experienced
depression and only 4% experienced anxiety,20 whereas
others found a considerable group of LVAD patients experi-
encing a depressive or adjustment disorder (21% and 37%–
50%, respectively).29,31 In trials (ie, the Randomized Evalu-
ation of Mechanical Assistance in the Treatment of
Congestive Heart Failure trial) comparing LVAD patients
using pulsatile devices with patients using optimal medical
treatment and transplant recipients, LVAD support was asso-
ciated with a significant improvement in health status and
depressive symptoms in contrast to medication alone
(P0.05 for both).26,30,32 However, LVAD patients do not
seem to attain the same level of health status compared with
transplant recipients, with transplant recipients experiencing
more improvements in mobility, self-care ability, physical
ability, and social functioning than LVAD patients.13,32
Health status instruments did not show a statistically signif-
icant difference between patient groups, and all health status
domains were not significantly better or worse when a
difference existed between groups.
PROs in Studies on Continuous-Flow Devices
The most intensively studied continuous-flow device used in
the studies included for the review was the HeartMate II
(Thoratec Inc). Other devices included the Micromed DeBakey
(Micromed Cardiovascular Inc, Houston, TX), INCORE (Berlin
Heart AG), Jarvik 2000 (Jarvik Heart, Inc, New York, NY), or
HVAD device (HeartWare Inc, Framingham, MA) (Table 2).
Almost all studies on patients with a continuous-flow LVAD
show significant improvements in mean health status scores,
using the MLHFQ, Kansas City Cardiomyopathy Question-
naire (KCCQ), SF-36, and EuroQol EQ-5D (EQ-5D), from
baseline up to the 3-, 6-, and 12-month follow-up (P0.05 for
all).18,25,27,34,35,37,38 Only the study by Kugler et al36 found no
significant improvement in health status using the SF-36 at
the 6-month follow-up. Whether this was due to psychosocial
problems or a lower physical exercise tolerance is not clear,
because both may ultimately restrict patients’ opportunities to
re-engage in professional and recreational activities, which
are known predictors for long-term health status.36
In recent years, several articles have been published on
comparative studies between LVAD patients with different
devices and in different clinical settings25,27,34,38 or between
LVAD patients and transplant recipients and healthy con-
trols.34,36 The HeartMate II trial had 2 arms that enabled the
investigators to analyze the health status within and between
patient groups supported by the HeartMate XVE or the
HeartMate II. At the 12-month follow-up, the health status of
patients receiving therapy via continuous-flow LVADs was
better compared with those receiving therapy via pulsatile
devices (MLHFQ, P0.03; KCCC-OSS [Overall Summary
Score], P0.06; KCCQ-CSS [Clinical Summary Score],
P0.12), likely caused by the improved durability, decrease
in complications, smaller size, and silent operation of the
continuous-flow device.27 Recently, the HeartMate II was
also compared with the HeartMate XVE and the Thoratec
pVAD in a commercial setting to investigate the relative
efficacy and risk profile, in patients enrolled in the Inter-
agency Registry for Mechanically Assisted Circulatory Sup-
port. Health status appeared to improve equally for the 2
groups of devices (P0.001) after 3 months to 1 year.38
Patients receiving therapy via pulsatile and continuous-flow
devices were not significantly different on symptoms of
anxiety, depression, and posttraumatic stress disorder.19 The
cross-sectional study of Meyer et al34 found no significant
differences in domain scores between 2 continuous-flow
systems: the centrifugal-flow pump Heartmate II and the
axial-flow pump HVAD.
From both arms of the HeartMate II trial, patients were also
selected based on their device indication (ie, bridge-to-
transplant or destination therapy) and compared on paired
health status scores. The group of LVAD patients indicated
for destination therapy had a higher improvement in median
health status scores between baseline and 6 months than the
group of LVAD patients indicated for bridge-to-transplant
therapy (MLHFQ, -40 vs -29 points; KCCQ-OSS, 39 vs 28
points; KCCQ-CSS, 36 vs 24 points, respectively).25 In this
study, 79% of the bridge-to-transplant patients and 92% of
the destination therapy patients with paired data had achieved
a clinically meaningful improvement of 5 points in their
KCCQ-OSS and KCCQ-CSS scores compared with
baseline.25
Compared with transplant recipients and healthy controls,
LVAD patients reported considerably poorer health status at
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baseline (P0.0032) and at the 6-month follow-up (P0.016),
especially with respect to mental health and physical func-
tioning34,36 and with respect to the social functioning, role
physical functioning, and role emotional functioning domains
of the SF-36.34
Overall, evidence on the impact of the duration of living
with an LVAD, the initial diagnosis, and sex and age
disparities in health status is scarce among LVAD patients.
Women tend to have been underrepresented in LVAD stud-
ies, with one study finding no significant sex differences
among LVAD patients (MLHFQ, P0.661; KCCQ-OSS,
P0.706; KCCQ-CSS, P0.371).18
Discussion
Summary of the Findings
This review indicates that LVAD patients experience an
improvement in health status, particularly in the first 3
months after LVAD implantation and discharge. This trend
was visible irrespective of the type of device (pulsatile vs
continuous-flow devices) and clinical setting (destination and
bridge-to-transplant therapy). Results also indicated that
LVAD patients supported by continuous-flow devices and
destination therapy show the greatest improvements in health
status after implantation.
Few studies have examined the prevalence of anxiety and
depression in LVAD patients, in particular in patients receiv-
ing therapy via continuous-flow LVADs. Patients supported
by pulsatile devices showed relatively high mean depression
scores just after LVAD implantation.26,29,31 The retrospective
study19 of Bunzel et al20 found no significant difference in
depression scores between patients receiving therapy via
pulsatile vs continuous-flow devices; these patients might be
more vulnerable to psychological distress, based on the higher
rate of complications and the characteristics of the device (eg,
short durability, large size, noise, and large batteries). Hence,
these differences in findings could well be explained by sample
size limitations, differences in subtype of devices, and the time
of collecting data.
The LVAD patients report better health status and fewer
symptoms of anxiety and depression when compared with
their partners and with patients receiving optimal medical
treatment, but not when compared with transplant recipients.
In contrast to transplant recipients, LVAD patients are recur-
rently reminded of their device because of the need to clean
the driveline insertion site and change batteries frequently.15
Furthermore, organ recipients appear to redefine “normal”
life and what it entails after transplantation.32
Overall, there was a substantial difference between the
studies in the handling and reporting of PROs, depending on
whether PROs were assessed as primary or secondary out-
comes. In Table 3, the details on the number of patients alive
from baseline to end of follow-up, the estimated percentage
of those patients having PRO data, and the cause of missing
data were outlined for all prospective studies assessing health
status in LVAD patients. Except for the Randomized Evalu-
ation of Mechanical Assistance in the Treatment of Conges-
tive Heart Failure trial,26 all studies on pulsatile devices
assessed health status as a primary outcome, whereas this
only holds true for 1 continuous-flow study.36 The percentage
of PRO data obtained from the patients alive over time was 92%
to 100% in the pulsatile device studies and 46% to 91% in the
continuous-flow device studies. At the end of the full study,
this percentage was unchanged for the pulsatile device studies
and was 49% to 89% for the continuous-flow device studies.
In 2 continuous-flow device studies, the follow-up period for
the PROs was shorter than the follow-up period for the full
study, causing an absence of PRO data at the final time
points.18,25 For those studies, the percentage of PRO data
obtained was calculated based on the number of patients alive
at the end of the PRO follow-up period rather than at the end
of the full study. Most studies indicated similar reasons for
the missing data (eg, patient exclusion, deceased, too ill, heart
transplantation, or dropout). None of the studies reported
cognitive limitations or psychological distress as a reason for
missing data.
Limitations of the Review
Because of the different time era of the studies included in
this review and the heterogeneity of the studies (differences
in follow-up assessments, sample sizes, and PRO assess-
ment), it was not possible to perform a formal meta-analysis.
Although increasing the statistical power of the findings by
excluding studies with a small sample size (N10), this
resulted in fewer articles eligible for inclusion. In turn, this
could have potentially created a bias toward results found in
larger studies. The proportion of female patients across
studies was relatively low; hence, it is not feasible to
generalize the findings to women with an LVAD. There was
a considerable difference in the percentage of missing PRO
data between the pulsatile and continuous-flow device stud-
ies. This is most probably caused by the fact that most of the
pulsatile device studies assessed PROs as primary outcomes
but was also because of shorter follow-up times, thereby
decreasing the chance of death, heart transplantation, and
drop out. Only 3 studies18,36,37 reported how they dealt with
loss of data, which included comparing the baseline charac-
teristics of patients for whom data were and were not
available or substituting the missing scores by the maximum
negative score of the used instrument. Correcting for missing
data did not affect the outcomes in these studies. Other
studies calculated the percentage and significance of im-
provement by simply comparing the group total scores of
patients with paired data between baseline and follow-up.
However, the number of patients with paired data decreases
significantly over time, which may increase the probability of
finding a significant improvement because the sicker patients
are usually lost to follow-up. More information is needed on
intraindividual changes and the proportion of patients who
experience a clinically relevant change.
Moreover, the instruments chosen for the study might not
have been sufficiently sensitive to tap LVAD-related changes
in health status, if present.36 Some instruments, such as the
KCCQ, have also not been used optimally, because authors
did not report subdomain scores. Finally, studies failed to
examine key predictors of intraindividual changes in PROs
over time or associations between PROs and other outcomes,
such as mortality and number of hospitalizations.
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Need for Assessing PROs in LVAD Patients
The importance of studying PROs, such as health status, is
gaining increased recognition because of the belief that an
illness, its treatment, and complications affect all domains of a
patient’s life and that the patient perspective is as valid as that of
the clinician when evaluating outcomes.39 In addition, informa-
tion on PROs is important for future patients and families who
have to make an informed decision regarding the option for
LVAD therapy. Information on PROs cannot be extracted from
patients’ medical records or a proxy and, therefore, PROs need
to be assessed in their own right. Thus, PROs may provide
important additional information to health care providers and
serve as targets for intervention in individual patients.8
Despite their importance, there is often a minor emphasis
placed on PROs, and they are rarely included as primary
outcomes in clinical LVAD trials.6 In particular, studies on
continuous-flow LVADs show a tendency to neglect anxiety
and depression. This is surprising given that 15% to 36% of
patients with heart failure experience depression,40,41 40%
experience anxiety,16 and 10% to 17% experience posttrau-
matic stress disorder.42,43 Symptoms of depression and anxi-
ety can be disabling15 and are associated with an increased
risk of declines in physical health,16 mortality, higher medi-
cation costs,15 noncompliance with treatment, malignan-
cies,44,45 and hospital readmissions.8 The limited available
evidence suggests that there may be a link between LVAD
technology and the patient’s psychological adjustment.5
Recommendations for Future Research and Care
of LVAD Patients
Because it has been widely established that LVAD therapy is
capable of enhancing the survival of patients with end-stage
heart failure, measuring PROs (eg, functional status, quality
of life, and psychological distress) in these patients deserves
a priority similar to survival in future LVAD studies. This
review indicates that PROs improve over time, yet it also
uncovers major shortcomings in their assessment, reflecting a
considerable knowledge gap in the optimal care for these
patients. More specific recommendations for future research
and clinical practice in LVAD therapy are given in Table 4.
In addition to the current interindividual approach (com-
paring changes in mean group scores over time), PROs
should also be analyzed using an intraindividual approach
focusing on the proportion of patients who experience a
clinical improvement or deterioration over time. Eventually,
this will create the possibility of risk stratifying patients and
enhancing optimal clinical practice.
Appropriate care should also be given when selecting PRO
measures, with a distinct preference for disease-specific mea-
sures, such as the KCCQ or MLHFQ. Patients are more likely to
Table 4. Recommendations for the Incorporation of PRO Assessments in Clinical Practice and Future Research
Variable Clinical Practice Future Research
Purpose of incorporating PROs in
clinical practice and research
PROs have unique prognostic value beyond physician-rated
measures and information derived from patients’ medical
status
Evaluate the impact of treatment, devices, and device
settings on PROs using both health status and
anxiety/depression measures
Inclusion of the patient perspective; no proxy measure
available from measures assessed in a standard clinical setting
Comparison of PROs between LVAD patients and other
groups (eg, patients receiving optimal medical
treatment, HTx) is necessary for informed political and
clinical decision making
PROs may facilitate communication between patients and
physicians
Compare the sensitivity of disease-specific and generic
PRO measures to detect changes over time; if
necessary, develop new disease-specific measures (eg,
to assess anxiety and depression)
PROs may enhance identification of high-risk patients whose
medical treatment needs to be optimized
PROs can be used as performance measures to evaluate the
quality of care
Recommendations for PROs as
primary outcomes in LVAD
research and therapy
Enables more accurate tracking of changes in patient’s
physical and psychological functioning over time and better
coordination of care (eg, individually tailored rehabilitation
programs)
Examine the correlation between clinical variables and
PROs and determine their relative importance for LVAD
patient prognosis
A no-risk, low-cost, and low-burden addition to clinical care Use both an interindividual and intraindividual approach
in data analyses
Adhere to CONSORT and STROBE statement guidelines
for reporting critical PRO data elements (eg, missing
data and clinically meaningful improvement)
Use of disease-specific questionnaires (eg, MLHFQ,
KCCQ) in studies with LVAD cohorts only
Incorporate PRO instruments for anxiety and depression
in studies on continuous-flow devices
Use prospective studies with large sample sizes
CONSORT, Consolidated Standards of Reporting Trials; MLHFQ, Minnesota Living with Heart Failure Questionnaire; STROBE, Strengthening the Reporting of
Observational Studies in Epidemiology.
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identify themselves in these instruments, thereby increasing the
response rate. In studies on continuous-flow devices, health
status was predominantly measured with the KCCQ or the
MLHFQ, with both measures showing similar results in various
large-scale LVAD studies.18,22,23,25,27 This suggests that these
measures are sensitive for detecting LVAD-related changes in
health status over time, if present. To capture psychological
morbidity in LVAD patients, the Heart Failure Symptom Check-
list or LVAD Stressor Scale could be used in addition to specific
anxiety/depression measures. Given the paucity of studies on
psychological functioning in LVAD patients, it is difficult to
recommend a specific instrument to use. The Patient Health
Questionnaire [PHQ-9] and the Generalized Anxiety Disorder
[GAD-7] Scale might be a way to start, because both instruments
have excellent psychometric properties. In addition, these mea-
sures are exempt from copyright and can be used free of charge.
It is paramount that future studies comply with the Consoli-
dated Standards of Reporting Trials [CONSORT] and the
Strengthening the Reporting of OBservational studies in Epide-
miology [STROBE] statements for reporting results of random-
ized trials and observational studies.46,47 These guidelines also
stipulate reporting of missing data and clinical relevance, as has
also been advocated by others.48,49 This is needed because, for
sufficiently large trials, it is possible to have a statistically
significant difference that may not be clinically meaningful.49 In
clinical practice, there needs to be a shift in LVAD rehabilitation
programs from survival to also focus on coping abilities and
health status of LVAD patients. These programs need to be
tailored to the individual patient and should also account for the
patient’s level of emotional functioning.
Conclusion
There is a paucity of studies on the patient perspective of
LVAD therapy. Initial evidence suggests an improvement in
health status, anxiety, and depression in the first months after
LVAD implantation. However, PRO scores of LVAD pa-
tients are still lower for physical, social, and emotional
functioning compared with transplant recipients. To advance
the field of LVAD research and to optimize the management
of an increasingly growing population of LVAD patients,
more well-designed large-scale studies on PROs are needed.
By these studies, we will be able to further elucidate the
psychological and social impact of LVAD therapy, thereby
creating the opportunity to improve the care for patients after
LVAD implantation and to provide important information
that is needed by patients and families for effective decision
making regarding whether LVAD implantation is aligned
with their own preferences and goals.
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CLINICAL PERSPECTIVE
Evidence suggests that patients receiving left ventricular assist device (LVAD) therapy experience an improvement in
health status over time, independent of device type and setting. However, although their physical disability becomes less
prominent after implantation, many patients experience difficulties with psychological adjustment, especially early after
implantation, which is associated with worrying about LVAD malfunction, complications, waiting for a donor heart, and
being away from family. Furthermore, overall functioning of LVAD patients is still more impaired compared with
transplant recipients on physical, social, and emotional functioning. Extensive information on patient-reported outcomes
in LVAD patients is limited, with many of the existing studies having methodological shortcomings. To advance the field
of LVAD research and to optimize the care of an increasingly growing population of LVAD patients, more well-designed
large-scale studies are needed to further elucidate the impact of LVAD therapy on patient-reported outcomes.
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